RHHVF Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of -- compared to Roche Holding AG's net margin of -2841.85%. Roche Holding AG's return on equity of 23.8% beat Addex Therapeutics's return on equity of 91.08%.

Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 239.75%. Given that Addex Therapeutics has higher upside potential than Roche Holding AG, analysts believe Addex Therapeutics is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.472, which suggesting that the stock is 52.822% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.646, suggesting its more volatile than the S&P 500 by 64.6%.

Roche Holding AG has a quarterly dividend of $10.97 per share corresponding to a yield of 3.42%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. Roche Holding AG's net income of -- is lower than Addex Therapeutics's net income of -$1.6M. Notably, Roche Holding AG's price-to-earnings ratio is 28.74x while Addex Therapeutics's PE ratio is 1.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.68x versus 24.16x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of -- compared to Roche Holding AG's net margin of -106.6%. Roche Holding AG's return on equity of 23.8% beat CRISPR Therapeutics AG's return on equity of -18.65%.

Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.80 which suggests that it could grow by 48.34%. Given that CRISPR Therapeutics AG has higher upside potential than Roche Holding AG, analysts believe CRISPR Therapeutics AG is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.472, which suggesting that the stock is 52.822% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.822, suggesting its more volatile than the S&P 500 by 82.156%.

Roche Holding AG has a quarterly dividend of $10.97 per share corresponding to a yield of 3.42%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. Roche Holding AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$136M. Notably, Roche Holding AG's price-to-earnings ratio is 28.74x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.68x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines has a net margin of -- compared to Roche Holding AG's net margin of 0.11%. Roche Holding AG's return on equity of 23.8% beat BeOne Medicines's return on equity of -11.54%.

Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines has an analysts' consensus of $332.60 which suggests that it could grow by 19.14%. Given that BeOne Medicines has higher upside potential than Roche Holding AG, analysts believe BeOne Medicines is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.472, which suggesting that the stock is 52.822% less volatile than S&P 500. In comparison BeOne Medicines has a beta of 0.282, suggesting its less volatile than the S&P 500 by 71.823%.

Roche Holding AG has a quarterly dividend of $10.97 per share corresponding to a yield of 3.42%. BeOne Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. BeOne Medicines pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than BeOne Medicines quarterly revenues of $1.1B. Roche Holding AG's net income of -- is lower than BeOne Medicines's net income of $1.3M. Notably, Roche Holding AG's price-to-earnings ratio is 28.74x while BeOne Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.68x versus 7.17x for BeOne Medicines. Usually stocks with elevated PS ratios are considered overvalued.